EYSUVIS: payments to doctors
Payments that named EYSUVIS as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.6M
- Providers
- 10,720
- Transactions
- 33,057
- Average per transaction
- $79
The per-transaction average — $79 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 10,720 providers the average total is $245, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Kala Pharmaceuticals, Inc. | $2,373,779 | 90.4% |
| Alcon | $250,829 | 9.6% |
| Alcon Research LLC | $83 | 0.0% |